Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 86Recurrence 18Neoplasms 6Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Sarcoma, Kaposi 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Chromosome 17 deletion 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Plasmacytoma 1Plasmablastic Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Dexamethasone 17Lenalidomide 15Bortezomib 12Cyclophosphamide 7fludarabine 6carfilzomib 6Melphalan 6daratumumab 5Calcium Dobesilate 5pomalidomide 3gamma-Globulins 3fludarabine phosphate 3belantamab mafodotin 3Whole-Body Irradiation 3Trimethoprim, Sulfamethoxazole Drug Combination 3Tacrolimus 3Mycophenolic Acid 3isatuximab 2elotuzumab 2Sirolimus 2Prednisone 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Ciprofloxacin 2Amoxicillin-Potassium Clavulanate Combination 2venetoclax 1thymoglobulin 1siltuximab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × pomalidomide × 1 year × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Takeda

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

K36 Therapeutics, Inc.

Phase 1 Recruiting
125 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡